Adaptive power priors with empirical Bayes for clinical trials

Pharmaceutical Statistics

Volumn 16, Issue 5, 2017, Pages 349-360

  Gravestock, Isaac ^a   Held, Leonhard ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Bayesian; clinical trials; empirical Bayes; historical data; power prior

Indexed keywords

CLINICAL TRIAL; HUMAN; STATISTICAL SIGNIFICANCE; BAYES THEOREM; CLINICAL TRIAL (TOPIC); PROBABILITY;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; PROBABILITY;

EID: 85020117425     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1814     Document Type: Article

References (29)

1. K. Viele, S. Berry, B. Neuenschwander, B. Amzal, F. Chen, N. Enas, B. Hobbs, J. G. Ibrahim, N. Kinnersley, S. Lindborg, Pharm. Stat. 2014, 13(1), 41.
2. M.-H. Chen, J. G. Ibrahim, Q.-M. Shao, J. Stat. Plan. Infer. 2000, 84(11), 121.
3. J. G. Ibrahim, M.-H. Chen, Stat. Sci. 2000, 15(1), 46.
4. J. G. Ibrahim, M.-H. Chen, D. Sinha, J. Am. Stat. Assoc. 2003, 98(461), 204.
5. M.-H. Chen, J. G. Ibrahim, Bayesian Anal. 2006, 1(3), 551.
6. J. G. Ibrahim, M.-H. Chen, Y. Gwon, F. Chen, Stat. Med. 2015, 34(28), 3724.
7. Y. Duan, E. P. Smith, K. Ye, J. Agric. Biol. Environ. Stat. 2006, 11(2), 151.
8. Y. Duan, K. Ye, E. P. Smith, Environmetrics 2006, 17(1), 95.
9. B. Neuenschwander, M. Branson, D. J. Spiegelhalter, Statistics in Medicine 2009, 28(28), 3562.
10. B. P. Hobbs, B. P. Carlin, S. J. Mandrekar, D. J. Sargent, Biometrics 2011, 67(3), 1047.
11. B. Neelon, J. A. O'Malley, J. Biometrics. Biostat. 2010, 1(1), 1.
12. B. P. Carlin, T. A. Louis, Bayes and Empirical Bayes Methods for Data Analysis, Chapman and Hall/CRC Texts in Statistical Science Taylor and Francis 1996.
13. B. P. Hobbs, D. J. Sargent, B. P. Carlin, Bayesian Anal. 2012, 7(3), 639.
14. L. Held, R. Sauter, Adaptive prior weighting in generalized linear models, 2017, 73(1), 242.
15. T. Friede, M. Kieser, Stat. Med. 2001, 20(24), 3861.
16. B. P. Hobbs, B. P. Carlin, D. J. Sargent, Clin. Trials 2013, 10(3), 430.
17. Center for drug evaluation and research (FDA), Guidance for Industry: Antibacterial Therapies for Patients With Unmet Medical Need for the Treatment of Serious Bacterial Diseases, 2013.
18. G. Campbell, J. Biopharm. Stat. 2011, 21(5), 871.
19. S. J. Pocock, J. Chronic Dis. 1976, 29(3), 175.
20. D. J. Spiegelhalter, K. R. Abrams, J. P. Myles, Bayesian Approaches to Clinical Trials and Health-Care Evaluation, John Wiley & Sons 2004.
21. Y. Duan, A Modified Bayesian Power Prior Approach with Applications in Water Quality Evaluation, PhD thesis, Virginia Polytechnic Institute and State University, 2005.
22. G. E. Box, J. R. Stat. Soc. Series A (General) 1980, 143(4), 383.
23. M. Evans, H. Moshonov, Bayesian Anal. 2006, 1(4), 893.
24. D. Dejardin, J. van Rosmalen, E. Lesaffre, Including historical data in the analysis of clinical trials using the modified power prior, Presentation at Bayes Pharma meeting 2014, http://www.bayes-pharma.org/bayes2014docs/Day1/Dejardin.pdf, 2014.
25. E. Rubinstein, S. K. Cammarata, T. H. Oliphant, R. G. Wunderink, Clin. Infect. Dis. 2001, 32(3), 402.
26. R. G. Wunderink, S. K. Cammarata, T. H. Oliphant, M. H. Kollef, Clin. Ther. 2003, 25(3), 980.
27. H. Schmidli, S. Gsteiger, S. Roychoudhury, A. O'Hagan, D. Spiegelhalter, B. Neuenschwander, Biometrics 2014, 70(4), 1023.
28. R. L. Cuffe, Stat. Med. 2011, 30, 1329.
29. M. J. Bayarri, J. O. Berger, Stat. Sci. 2004, 19, 58.